Effects of previous infection, vaccination, and hybrid immunity against symptomatic Alpha, Beta, and Delta infections
Authors:
- Heba N. N. AltarawnehHAHeba N. N. Altarawneh
- Hiam ChemaitellyHCHiam Chemaitelly
- Houssein H. AyoubHAHoussein H. Ayoub
- Patrick TangPTPatrick Tang
- Hadi M. YassineHYHadi M. Yassine
- Hebah A. Al-KhatibHAHebah A. Al-Khatib
- Peter CoylePCPeter Coyle
- Zaina Al-KanaaniZAZaina Al-Kanaani
- Einas Al-KuwariEAEinas Al-Kuwari
- Andrew JeremijenkoAJAndrew Jeremijenko
Preprint
Abstract
Background: Protection against SARS-CoV-2 symptomatic infection and severe COVID-19 of previous infection, mRNA two-dose vaccination, mRNA three-dose vaccination, and hybrid immunity of previous infection and vaccination were investigated in Qatar for the Alpha, Beta, and Delta variants. Methods: Six national, matched, test-negative, case-control studies were conducted between January 18-December 18, 2021 on a sample of 239,120 PCR-positive tests and 6,103,365 PCR-negative tests. Results: Effectiveness of previous infection against Alpha, Beta, and Delta reinfection was 89.5% (95% CI: 85.5-92.3%), 87.9% (95% CI: 85.4-89.9%), and 90.0% (95% CI: 86.7-92.5%), respectively. Effectiveness of two-dose BNT162b2 vaccination against Alpha, Beta, and Delta infection was 90.5% (95% CI, 83.9-94.4%), 80.5% (95% CI: 79.0-82.0%), and 58.1% (95% CI: 54.6-61.3%), respectively. Effectiveness of three-dose BNT162b2 vaccination against Delta infection was 91.7% (95% CI: 87.1-94.7%). Effectiveness of hybrid immunity of previous infection and two-dose BNT162b2 vaccination was 97.4% (95% CI: 95.4-98.5%) against Beta infection and 94.5% (95% CI: 92.8-95.8%) against Delta infection. Effectiveness of previous infection and three-dose BNT162b2 vaccination was 98.1% (95% CI: 85.7-99.7%) against Delta infection. All five forms of immunity had >90% protection against severe, critical, or fatal COVID-19 regardless of variant. Similar effectiveness estimates were observed for mRNA-1273. Conclusions: All forms of natural and vaccine immunity prior to Omicron introduction provided strong protection against infection and severe COVID-19. Hybrid immunity conferred the strongest protection and its level was consistent with previous-infection immunity and vaccine immunity acting independently of each other.Keywords
This publication has 43 references indexed in Scilit:
- COVID-19 (SARS-CoV-2) outbreak monitoring using wastewater-based epidemiology in QatarScience of The Total Environment, 2021
- Herd Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 10 Communities, QatarEmerging Infectious Diseases, 2021
- Characterizing the Qatar advanced-phase SARS-CoV-2 epidemicScientific Reports, 2021
- Multiplexed RT-qPCR to screen for SARS-COV-2 B.1.1.7, B.1.351, and P.1 variants of concern v32021
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 VaccineNew England Journal of Medicine, 2021
- Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19Journal of Global Health, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineNew England Journal of Medicine, 2020
- Case-control vaccine effectiveness studies: Preparation, design, and enrollment of cases and controlsVaccine, 2017
- The test-negative design for estimating influenza vaccine effectivenessVaccine, 2013
- Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational ResearchCommunications in Statistics - Simulation and Computation, 2009